Stay updated on Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial page.

Latest updates to the Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial page
- Check3 days agoNo Change Detected
- Check10 days agoChange DetectedPublications section updated to clarify that publications are provided voluntarily by contributors who enter information about the study results, and the site revision badges were updated from v3.2.0 to v3.3.2.SummaryDifference0.1%

- Check17 days agoChange DetectedPublications section updated: a 2014 NEJM paper on CTLA-4 blockade was added with erratum details, and the previous citation entry was removed.SummaryDifference0.4%

- Check39 days agoChange DetectedThe two screenshots show the same Study Details page with identical trial information (title, conditions, eligibility criteria, interventions, outcomes, and locations). No core content or data elements were added or removed.SummaryDifference0.4%

- Check61 days agoChange Detected- Removed version v3.1.0 and added notice about government funding lapse and current NIH Clinical Center status with links, plus new version tag v3.2.0. The page now communicates operating status details and a newer software version.SummaryDifference2%

- Check68 days agoChange DetectedVersion updated from v3.0.2 to v3.1.0; core page metadata updated to reflect a new release.SummaryDifference0.0%

- Check83 days agoChange DetectedVersion updated from v3.0.1 to v3.0.2 and the 'Back to Top' element was removed; this suggests minor updates and a small UI tweak, with no evident changes to core content.SummaryDifference0.1%

Stay in the know with updates to Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib Pembrolizumab in Hepatobiliary Tumors Clinical Trial page.